TxCell is a biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need.
TxCell is targeting a range of autoimmune diseases (both T-cell and B-cell-mediated) including Crohn’s disease, lupus nephritis, bullous pemphigoid and multiple sclerosis, as well as transplantation-related inflammatory disorders.
|Shareholder Letter N°1 (in French) - 15/11/2016||
TxCell presentation - ARM EU Advanced Therapies Investor Day - 03/11/2016
Half-year financial results - Conference call and webcast
A conference call and webcast in English will be held on Wednesday, September 28 at 3:30pm CET. To participate:
- Dial-in: +33 (0) 1 72 00 15 10
- PIN Code: 20587658#
- Webcast link: http://www.anywhereconference.com?UserAudioMode=DATA&Name=&Conference=135303497&PIN=20587658
You may also download the presentation in PDF.
Following the live call, a replay will be available for 90 days. To listen to the replay, please dial: +33 (0)1 72 00 15 00 / 303497#
|2015 Registration Document (Document de Référence) - 24/05/2016||
Corporate Presentation - December 1st, 2016
Arnaud Foussat, "Multiple ways to genetically alter T cells", MedNous, Vol 10, N° 7, July-August 2016, 6-7.